According to the company on the 20th, Hexasim®, the first hexavalent mixed vaccine in Korea, is a complete liquid formulation combo vaccine containing hepatitis B antigen developed by Sanofi Pasteur. It can prevent invasive diseases caused by six infectious diseases such as diphtheria, tetanus, whooping cough, hepatitis B, polio (polio), and Haemophilus influenza b (Hib). In Korea, in April 2020, it obtained a license for an imported item from the Ministry of Food and Drug Safety.
|
![[참고사진] Sanofi Pasteur Hexasim_Product Picture](https://i0.wp.com/img.asiatoday.co.kr/file/2021y/04m/20d/2021042001001944600121591.jpg?w=560&ssl=1)
Hexasim® is administered three times at 2, 4 and 6 months to infants 2 months and older who received the hepatitis B vaccine at 0 months of age. The company explained that the number of vaccinations was reduced up to two times compared to the pentagonal combination vaccine and the hepatitis B vaccine alone, and the number of vaccinations was reduced by up to eight times compared to the single vaccination that prevents six infectious diseases.
Hexasim® has confirmed the immunogenicity through basic vaccination and a safety profile similar to that of the control group in all antigens corresponding to six infectious diseases through global clinical studies including Korea, the company added.
CEO Pascal Robin Sanofi Pasteur said, “In the current situation where it is burdensome to go out and visit hospitals due to Corona 19, I hope that we can increase the convenience of vaccination for infants and their guardians so that we can inoculate essential basic vaccinations for infants after birth in a timely manner to protect their health.” Said.
